Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Activation of Nicotinic Acetylcholine α7 Receptor Attenuates Progression of Monocrotaline-Induced Pulmonary Hypertension in Rats by Downregulating the NLRP3 Inflammasome.

Deng Y, Guo SL, Wei B, Gao XC, Zhou YC, Li JQ.

Front Pharmacol. 2019 Feb 26;10:128. doi: 10.3389/fphar.2019.00128. eCollection 2019.

2.

Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats.

Tang B, Chen GX, Liang MY, Yao JP, Wu ZK.

Int J Cardiol. 2015 Feb 1;180:134-41. doi: 10.1016/j.ijcard.2014.11.161. Epub 2014 Nov 25.

3.

Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.

Shi R, Wei Z, Zhu D, Fu N, Wang C, Yin S, Liang Y, Xing J, Wang X, Wang Y.

Pulm Pharmacol Ther. 2018 Feb;48:124-135. doi: 10.1016/j.pupt.2017.11.003. Epub 2017 Nov 10.

PMID:
29133079
4.

Activating α7 nicotinic acetylcholine receptor inhibits NLRP3 inflammasome through regulation of β-arrestin-1.

Ke P, Shao BZ, Xu ZQ, Chen XW, Wei W, Liu C.

CNS Neurosci Ther. 2017 Nov;23(11):875-884. doi: 10.1111/cns.12758. Epub 2017 Sep 21.

PMID:
28941191
5.

Role of P2X7R in the development and progression of pulmonary hypertension.

Yin J, You S, Liu H, Chen L, Zhang C, Hu H, Xue M, Cheng W, Wang Y, Li X, Shi Y, Li N, Yan S, Li X.

Respir Res. 2017 Jun 24;18(1):127. doi: 10.1186/s12931-017-0603-0.

6.

Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.

Yang PS, Kim DH, Lee YJ, Lee SE, Kang WJ, Chang HJ, Shin JS.

Respir Res. 2014 Nov 25;15:148. doi: 10.1186/s12931-014-0148-4. Erratum in: Respir Res. 2016 Nov 4;17 (1):142.

7.

Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats.

Dahal BK, Kosanovic D, Kaulen C, Cornitescu T, Savai R, Hoffmann J, Reiss I, Ghofrani HA, Weissmann N, Kuebler WM, Seeger W, Grimminger F, Schermuly RT.

Respir Res. 2011 May 2;12:60. doi: 10.1186/1465-9921-12-60.

8.

Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.

Shao A, Wu H, Hong Y, Tu S, Sun X, Wu Q, Zhao Q, Zhang J, Sheng J.

Mol Neurobiol. 2016 Jul;53(5):3462-3476. doi: 10.1007/s12035-015-9242-y. Epub 2015 Jun 20.

PMID:
26091790
9.

Altered mTOR and Beclin-1 mediated autophagic activation during right ventricular remodeling in monocrotaline-induced pulmonary hypertension.

Deng Y, Wu W, Guo S, Chen Y, Liu C, Gao X, Wei B.

Respir Res. 2017 Mar 24;18(1):53. doi: 10.1186/s12931-017-0536-7.

10.

Cardiopulmonary protective effects of the selective FXR agonist obeticholic acid in the rat model of monocrotaline-induced pulmonary hypertension.

Vignozzi L, Morelli A, Cellai I, Filippi S, Comeglio P, Sarchielli E, Maneschi E, Vannelli GB, Adorini L, Maggi M.

J Steroid Biochem Mol Biol. 2017 Jan;165(Pt B):277-292. doi: 10.1016/j.jsbmb.2016.07.004. Epub 2016 Jul 15.

PMID:
27425465
11.

Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model.

Comeglio P, Filippi S, Sarchielli E, Morelli A, Cellai I, Corno C, Adorini L, Vannelli GB, Maggi M, Vignozzi L.

J Endocrinol Invest. 2019 Jan 23. doi: 10.1007/s40618-019-1009-2. [Epub ahead of print]

PMID:
30674010
12.

Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension.

Huang WC, Ke MW, Cheng CC, Chiou SH, Wann SR, Shu CW, Chiou KR, Tseng CJ, Pan HW, Mar GY, Liu CP.

PLoS One. 2016 Feb 3;11(2):e0142476. doi: 10.1371/journal.pone.0142476. eCollection 2016.

13.

Docosahexaenoic acid inhibits monocrotaline-induced pulmonary hypertension via attenuating endoplasmic reticulum stress and inflammation.

Chen R, Zhong W, Shao C, Liu P, Wang C, Wang Z, Jiang M, Lu Y, Yan J.

Am J Physiol Lung Cell Mol Physiol. 2018 Feb 1;314(2):L243-L255. doi: 10.1152/ajplung.00046.2017. Epub 2017 Nov 2.

14.

Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.

Lu J, Shimpo H, Shimamoto A, Chong AJ, Hampton CR, Spring DJ, Yada M, Takao M, Onoda K, Yada I, Pohlman TH, Verrier ED.

J Thorac Cardiovasc Surg. 2004 Dec;128(6):850-9.

15.

Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats.

Tofovic SP, Salah EM, Mady HH, Jackson EK, Melhem MF.

J Cardiovasc Pharmacol. 2005 Oct;46(4):430-7.

PMID:
16160593
16.

Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline.

Voelkel NF, Tuder RM, Bridges J, Arend WP.

Am J Respir Cell Mol Biol. 1994 Dec;11(6):664-75.

PMID:
7946395
17.

Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.

Homma N, Morio Y, Takahashi H, Yamamoto A, Suzuki T, Sato K, Muramatsu M, Fukuchi Y.

Respiration. 2006;73(1):105-12. Epub 2005 Oct 1.

PMID:
16432296
18.

Alpha7 Nicotine Acetylcholine Receptor Agonist PNU-282987 Attenuates Acute Lung Injury in a Cardiopulmonary Bypass Model in Rats.

Ge J, Tian J, Yang H, Hou L, Wang Z, He Z, Wang X.

Shock. 2017 Apr;47(4):474-479. doi: 10.1097/SHK.0000000000000744.

PMID:
27661000
19.

Selective activation of angiotensin AT2 receptors attenuates progression of pulmonary hypertension and inhibits cardiopulmonary fibrosis.

Bruce E, Shenoy V, Rathinasabapathy A, Espejo A, Horowitz A, Oswalt A, Francis J, Nair A, Unger T, Raizada MK, Steckelings UM, Sumners C, Katovich MJ.

Br J Pharmacol. 2015 May;172(9):2219-31. doi: 10.1111/bph.13044. Epub 2015 Feb 27.

20.

Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.

Zhuang W, Lian G, Huang B, Du A, Xiao G, Gong J, Xu C, Wang H, Xie L.

Exp Biol Med (Maywood). 2018 Aug;243(12):995-1003. doi: 10.1177/1535370218794128. Epub 2018 Aug 12. Erratum in: Exp Biol Med (Maywood). 2018 Sep;243(13):NP1-NP2.

PMID:
30099957

Supplemental Content

Support Center